These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23998360)

  • 1. Bcl-2 associated with positive symptoms of schizophrenic patients in an acute phase.
    Tsai MC; Liou CW; Lin TK; Lin IM; Huang TL
    Psychiatry Res; 2013 Dec; 210(3):735-8. PubMed ID: 23998360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs.
    Tsai MC; Liou CW; Lin TK; Lin IM; Huang TL
    Psychiatry Res; 2013 Oct; 209(3):284-90. PubMed ID: 23497820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
    Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
    Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone in first-episode schizophrenia.
    Cesková E; Prikryl R; Kaspárek T
    Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
    J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.
    Si TM; Zhang YL; Feng Y; Zhuo JM; Cai S; Zhang L
    Psychiatry Res; 2019 Apr; 274():301-305. PubMed ID: 30831454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
    Canuso CM; Bossie CA; Turkoz I; Alphs L
    Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study].
    Strzelecki D; Kropiwnicki P; Rabe-Jabłońska J
    Psychiatr Pol; 2013; 47(4):609-20. PubMed ID: 24946468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilirubin concentration correlates with positive symptoms in patients with schizophrenia.
    Widschwendter CG; Rettenbacher MA; Kemmler G; Edlinger M; Baumgartner S; Fleischhacker WW; Hofer A
    J Clin Psychiatry; 2016 Apr; 77(4):512-6. PubMed ID: 27035280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cortisol and DHEA-S levels in schizophrenic patients with different response to antipsychotic therapy: association with psychopathology.
    Babinkostova Z; Stefanovski B; Janicevic-Ivanovska D; Samardziska V; Stojanovska L
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):175-83. PubMed ID: 26076787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
    Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.